Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | VEGFA | Direct | 4 | ||||||||
| ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine | VEGFA | Direct | 3 | ||||||||
| bevacizumab | VEGFA | Direct | 3 | ||||||||
| 5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin | VEGFA | Direct | 2 | ||||||||
| 5fu, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin | VEGFA | Direct | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | VEGFA | Direct | 2 | ||||||||
| bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis | VEGFA | Direct | 2 | ||||||||
| osimertinib, bevacizumab, osimertinib | VEGFA | Direct | 2 | ||||||||
| pd-1 inhibitor, bevacizumab, carboplatin, cisplatin, pemtrexed | VEGFA | Direct | 2 | ||||||||
| pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin | VEGFA | Direct | 2 | ||||||||
| pemetrexed, bevacizumab | VEGFA | Direct | 2 | ||||||||
| tucidinostat (chidamide), pd-1 inhibitor (toripalimab), bevacizumab | VEGFA | Direct | 2 | ||||||||
| 3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy | VEGFA | Direct | 1 | ||||||||
| 3-dimensional conformal radiation therapy, bevacizumab, intensity-modulated radiation therapy, laboratory biomarker analysis, placebo, quality-of-life assessment, temozolomide | VEGFA | Direct | 1 | ||||||||
| abemaciclib, bevacizumab | VEGFA | Direct | 1 | ||||||||
| amgen 386, bevacizumab | VEGFA | Direct | 1 | ||||||||
| andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel | VEGFA | Direct | 1 | ||||||||
| anetumab ravtansine, bevacizumab, paclitaxel | VEGFA | Direct | 1 | ||||||||
| ang1005, bevacizumab | VEGFA | Direct | 1 | ||||||||
| anti-endoglin chimeric monoclonal antibody trc105, bevacizumab, laboratory biomarker analysis, pharmacological study, quality-of-life assessment | VEGFA | Direct | 1 | ||||||||
| asc40 tablets, placebo tablets, bevacizumab | VEGFA | Direct | 1 | ||||||||
| atezolizumab injection, bevacizumab, transarterial chemoembolization | VEGFA | Direct | 1 | ||||||||
| atezolizumab, bevacizumab | VEGFA | Direct | 1 | ||||||||
| atezolizumab, bevacizumab, laboratory biomarker analysis, pharmacological study | VEGFA | Direct | 1 | ||||||||
| azd5335, saruparib (azd5305), bevacizumab, carboplatin | VEGFA | Direct | 1 | ||||||||
| bevacizumab, bevacizumab | VEGFA | Direct | 1 | ||||||||
| bevacizumab, biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, osimertinib | VEGFA | Direct | 1 | ||||||||
| bevacizumab, biospecimen collection, computed tomography, electronic health record review, hypofractionated radiation therapy, magnetic resonance imaging, retifanlimab | VEGFA | Direct | 1 | ||||||||
| bevacizumab, bkm120 | VEGFA | Direct | 1 | ||||||||
| bevacizumab, capecitabine, gemcitabine hydrochloride | VEGFA | Direct | 1 | ||||||||
| bevacizumab, capecitabine/oxaliplatin, fluorouracil/folinic acid/oxaliplatin, capecitabine, fluorouracil/folinic acid/irinotecan, fluorouracil +/- folinic acid | VEGFA | Direct | 1 | ||||||||
| bevacizumab, carmustine | VEGFA | Direct | 1 | ||||||||
| bevacizumab, cediranib maleate | VEGFA | Direct | 1 | ||||||||
| bevacizumab, cediranib, cediranib maleate, olaparib | VEGFA | Direct | 1 | ||||||||
| bevacizumab, chemotherapy, fractionated radiosurgery | VEGFA | Direct | 1 | ||||||||
| bevacizumab, chest radiation, concurrent chemotherapy | VEGFA | Direct | 1 | ||||||||
| bevacizumab, cisplatin, etoposide, radiation therapy | VEGFA | Direct | 1 | ||||||||
| bevacizumab, cisplatin, gemcitabine hydrochloride | VEGFA | Direct | 1 | ||||||||
| bevacizumab, cisplatin, irinotecan hydrochloride, proteomic profiling, diagnostic laboratory biomarker analysis, mass spectrometry, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy | VEGFA | Direct | 1 | ||||||||
| bevacizumab, dasatinib, placebo | VEGFA | Direct | 1 | ||||||||
| bevacizumab, docetaxel, oxaliplatin | VEGFA | Direct | 1 | ||||||||
| bevacizumab, erlotinib hydrochloride | VEGFA | Direct | 1 | ||||||||
| bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis | VEGFA | Direct | 1 | ||||||||
| bevacizumab, erlotinib, gemcitabine | VEGFA | Direct | 1 | ||||||||
| bevacizumab, everolimus, octreotide acetate | VEGFA | Direct | 1 | ||||||||
| bevacizumab, fludeoxyglucose f-18, irinotecan hydrochloride | VEGFA | Direct | 1 | ||||||||
| bevacizumab, gemcitabine hydrochloride, oxaliplatin | VEGFA | Direct | 1 | ||||||||
| bevacizumab, irinotecan | VEGFA | Direct | 1 | ||||||||
| bevacizumab, irinotecan hydrochloride | VEGFA | Direct | 1 | ||||||||
| bevacizumab, irinotecan hydrochloride, temozolomide | VEGFA | Direct | 1 | ||||||||
| bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging | VEGFA | Direct | 1 | ||||||||
| bevacizumab, laboratory biomarker analysis, pharmacological study, placebo administration, trebananib | VEGFA | Direct | 1 | ||||||||
| bevacizumab, laboratory biomarker analysis, pharmacological study, sapanisertib | VEGFA | Direct | 1 | ||||||||
| bevacizumab, lomustine, dna methylation analysis, laboratory biomarker analysis, cognitive assessment, quality-of-life assessment | VEGFA | Direct | 1 | ||||||||
| bevacizumab, lomustine, placebo, radiotherapy, temozolomide, soc agent | VEGFA | Direct | 1 | ||||||||
| bevacizumab, magnetic resonance spectroscopy (mrs), border zone stereotactic radiosurgery (bz-srs) | VEGFA | Direct | 1 | ||||||||
| bevacizumab, metronomic temozolomide | VEGFA | Direct | 1 | ||||||||
| bevacizumab, microbubble, low-intensity focused ultrasound | VEGFA | Direct | 1 | ||||||||
| bevacizumab, mln-518 (tandutinib), quality-of-life assessment | VEGFA | Direct | 1 | ||||||||
| bevacizumab, modified atkins diet | VEGFA | Direct | 1 | ||||||||
| bevacizumab, nimustine | VEGFA | Direct | 1 | ||||||||
| bevacizumab, novottf-l00a, quality of life assessment | VEGFA | Direct | 1 | ||||||||
| bevacizumab, onartuzumab, placebo | VEGFA | Direct | 1 | ||||||||
| bevacizumab, pd-l1 t-hank, n-803 | VEGFA | Direct | 1 | ||||||||
| bevacizumab, placebo, magnetic resonance imaging, quality-of-life assessment | VEGFA | Direct | 1 | ||||||||
| bevacizumab, prdr | VEGFA | Direct | 1 | ||||||||
| bevacizumab, radiation therapy | VEGFA | Direct | 1 | ||||||||
| bevacizumab, rindopepimut (cdx-110) with gm-csf, klh | VEGFA | Direct | 1 | ||||||||
| bevacizumab, sorafenib tosylate | VEGFA | Direct | 1 | ||||||||
| bevacizumab, tarceva, temozolomide | VEGFA | Direct | 1 | ||||||||
| bevacizumab, temozolomide | VEGFA | Direct | 1 | ||||||||
| bevacizumab, temozolomide, external beam radiation therapy | VEGFA | Direct | 1 | ||||||||
| bevacizumab, temozolomide, laboratory biomarker analysis, immunohistochemistry staining method, microarray analysis, dna methylation analysis | VEGFA | Direct | 1 | ||||||||
| bevacizumab, temozolomide, radiation therapy (xrt), topotecan | VEGFA | Direct | 1 | ||||||||
| bevacizumab, temozolomide, radiation therapy, placebo | VEGFA | Direct | 1 | ||||||||
| bevacizumab, temozolomide, rt (radiation therapy) | VEGFA | Direct | 1 | ||||||||
| bevacizumab, temozolomide, vorinostat | VEGFA | Direct | 1 | ||||||||
| bevacizumab, temsirolimus | VEGFA | Direct | 1 | ||||||||
| bevacizumab, th-302 | VEGFA | Direct | 1 | ||||||||
| bevacizumab, tvb-2640 | VEGFA | Direct | 1 | ||||||||
| bi 905711, folfiri, bevacizumab | VEGFA | Direct | 1 | ||||||||
| cadonilimab, bevacizumab, cryoablation | VEGFA | Direct | 1 | ||||||||
| capecitabine, bevacizumab | VEGFA | Direct | 1 | ||||||||
| capecitabine, radiation therapy, bevacizumab, therapeutic conventional surgery, gemcitabine hydrochloride | VEGFA | Direct | 1 | ||||||||
| capecitabine, temozolomide, bevacizumab | VEGFA | Direct | 1 | ||||||||
| cetuximab, bevacizumab, irinotecan | VEGFA | Direct | 1 | ||||||||
| cetuximab, gemcitabine hydrochloride, bevacizumab, erlotinib hydrochloride | VEGFA | Direct | 1 | ||||||||
| cisplatin, etoposide, bevacizumab, laboratory biomarker analysis | VEGFA | Direct | 1 | ||||||||
| cisplatin, irinotecan hydrochloride, bevacizumab, laboratory biomarker analysis | VEGFA | Direct | 1 | ||||||||
| dalteparin, gemcitabine hydrochloride, diagnostic laboratory biomarker analysis | VEGFA | Direct | 1 | ||||||||
| dalteparin, radiation therapy | VEGFA | Direct | 1 | ||||||||
| docetaxel, cisplatin, fluorouracil, bevacizumab, leucovorin | VEGFA | Direct | 1 | ||||||||
| dsp-7888 dosing emulsion, bevacizumab | VEGFA | Direct | 1 | ||||||||
| durvalumab, doxorubicin-eluting beads, tace, bevacizumab, tremelimumab | VEGFA | Direct | 1 | ||||||||
| durvalumab, standard radiotherapy, bevacizumab | VEGFA | Direct | 1 | ||||||||
| endoscopic variceal ligation, carvedilol | VEGFA | Direct | 1 | ||||||||
| enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) | VEGFA | Direct | 1 | ||||||||
| epacadostat, bevacizumab, radiation therapy, peripheral blood draw, retifanlimab | VEGFA | Direct | 1 | ||||||||
| epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan | VEGFA | Direct | 1 | ||||||||
| erlotinib hydrochloride, cetuximab, bevacizumab, laboratory biomarker analysis | VEGFA | Direct | 1 |